Literature DB >> 28473080

ACR Appropriateness Criteria® Prostate Cancer-Pretreatment Detection, Surveillance, and Staging.

Fergus V Coakley1, Aytekin Oto2, Lauren F Alexander3, Brian C Allen4, Brian J Davis5, Adam T Froemming5, Pat F Fulgham6, Keyanoosh Hosseinzadeh7, Christopher Porter8, V Anik Sahni9, David M Schuster3, Timothy N Showalter10, Aradhana M Venkatesan11, Sadhna Verma12, Carolyn L Wang13, Erick M Remer14, Steven C Eberhardt15.   

Abstract

Despite the frequent statement that "most men die with prostate cancer, not of it," the reality is that prostate cancer is second only to lung cancer as a cause of death from malignancy in American men. The primary goal during baseline evaluation of prostate cancer is disease characterization, that is, establishing disease presence, extent (local and distant), and aggressiveness. Prostate cancer is usually diagnosed after the finding of a suspicious serum prostate-specific antigen level or digital rectal examination. Tissue diagnosis may be obtained by transrectal ultrasound-guided biopsy or MRI-targeted biopsy. The latter requires a preliminary multiparametric MRI, which has emerged as a powerful and relatively accurate tool for the local evaluation of prostate cancer over the last few decades. Bone scintigraphy and CT are primarily used to detect bone and nodal metastases in patients found to have intermediate- or high-risk disease at biopsy. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.
Copyright © 2017 American College of Radiology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AUC; Appropriate Use Criteria; Appropriateness Criteria; cancer; imaging; prostate; staging

Mesh:

Substances:

Year:  2017        PMID: 28473080     DOI: 10.1016/j.jacr.2017.02.026

Source DB:  PubMed          Journal:  J Am Coll Radiol        ISSN: 1546-1440            Impact factor:   5.532


  14 in total

1.  Biparametric MRI prior to Radical Radiation Therapy for Prostate Cancer in a Caribbean Population: Implications for Risk Group Stratification and Treatment.

Authors:  Maria A Gosein; Dylan Narinesingh; Shastri Motilal; Adrian P Ramkissoon; Cristal M Goetz; Kristy Sadho; Murrie D Mosodeen; Renee Banfield
Journal:  Radiol Imaging Cancer       Date:  2020-07-31

2.  Cowper's gland hyperplasia: A potential pitfall at MRI of the prostate.

Authors:  Omar Kamal; Bryan R Foster; Kevin Turner; Sadhna Verma; Sungmin Woo; Tharakeswara K Bathala; Fergus V Coakley
Journal:  Clin Imaging       Date:  2021-08-08       Impact factor: 2.420

3.  Staging 68 Ga-PSMA PET/CT in 963 consecutive patients with newly diagnosed prostate cancer: incidence and characterization of skeletal involvement.

Authors:  Mikhail Kesler; Kosta Kerzhner; Ido Druckmann; Jonathan Kuten; Charles Levine; David Sarid; Daniel Keizman; Ofer Yossepowitch; Einat Even-Sapir
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-12-27       Impact factor: 10.057

Review 4.  Magnetic resonance imaging in active surveillance-a modern approach.

Authors:  Francesco Giganti; Caroline M Moore
Journal:  Transl Androl Urol       Date:  2018-02

5.  Expression and significance of PTEN and Claudin-3 in prostate cancer.

Authors:  Xinglong Ye; Lijing Zhao; Jing Kang
Journal:  Oncol Lett       Date:  2019-04-03       Impact factor: 2.967

Review 6.  Diagnosis of prostate cancer.

Authors:  Jean-Luc Descotes
Journal:  Asian J Urol       Date:  2019-02-14

7.  Total-Body 68Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines.

Authors:  Kelsey L Pomykala; Johannes Czernin; Tristan R Grogan; Wesley R Armstrong; John Williams; Jeremie Calais
Journal:  J Nucl Med       Date:  2019-09-20       Impact factor: 11.082

8.  Diagnostic performance of diffusion-weighted imaging for prostate cancer: Peripheral zone versus transition zone.

Authors:  Hakmin Lee; Sung Il Hwang; Hak Jong Lee; Seok-Soo Byun; Sang Eun Lee; Sung Kyu Hong
Journal:  PLoS One       Date:  2018-06-22       Impact factor: 3.240

9.  Clinical implementation of MRI-based organs-at-risk auto-segmentation with convolutional networks for prostate radiotherapy.

Authors:  Mark H F Savenije; Matteo Maspero; Gonda G Sikkes; Jochem R N van der Voort van Zyp; Alexis N T J Kotte; Gijsbert H Bol; Cornelis A T van den Berg
Journal:  Radiat Oncol       Date:  2020-05-11       Impact factor: 3.481

Review 10.  The use of prostate MR for targeting prostate biopsies.

Authors:  R Phelps Kelley; Ronald J Zagoria; Hao G Nguyen; Katsuto Shinohara; Antonio C Westphalen
Journal:  BJR Open       Date:  2019-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.